Surrozen SRZN
NASDAQ SRZN
$22.25 -0.29 (-1.29%)
As of: Sep 4, 2026 · 1:26 PM EDT

Surrozen (SRZN) Consolidated Net Income (2020 - 2026)

Surrozen (SRZN) posted quarterly Consolidated Net Income of -$32.5 million for Q1 2026, down 126.42% year-over-year from $123.0 million in Q1 2025, and down 259.1% quarter-over-quarter from -$9.1 million in Q4 2025.

Analysis

Surrozen (SRZN) Consolidated Net Income (2020 - 2026) Analysis & Trends

Surrozen's Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$32.5 million for Q1 2026.

  • In Q1 2026, Consolidated Net Income fell 126.42% year-over-year to -$32.5 million; the TTM figure through Mar 2026 stood at -$76.6 million (up 10.05% YoY), while the FY2025 annual figure was -$51.9 million, up 31.43% from the prior year.
  • Consolidated Net Income for Q1 2026 stood at -$32.5 million, down from -$9.1 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $104000.0 in Q3 2024, with the low at -$60.1 million in Q4 2024.
  • The 5-year median for Consolidated Net Income is -$14.7 million (2023), against an average of -$17.5 million.
  • The sharpest annual moves came in 2024 and 2025: Consolidated Net Income surged 100.71% in 2024, then plunged 17616.35% in 2025.
  • Surrozen's Consolidated Net Income stood at -$1.7 million in 2022, then plunged by 443.05% to -$9.2 million in 2023, then tumbled by 551.78% to -$60.1 million in 2024, then surged by 84.94% to -$9.1 million in 2025, then plunged by 259.1% to -$32.5 million in 2026.
  • Business Quant data shows SRZN's Consolidated Net Income at -$32.5 million in Q1 2026, -$9.1 million in Q4 2025, and -$18.2 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 601.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 81.49 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -13.27 Mn
10 Surrozen 259.50 Mn 259.50 Mn - -9.43 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.43 Mn
Mar 31, 2026 -9.54 Mn
Dec 31, 2025 -11.85 Mn
Sep 30, 2025 -9.97 Mn
Jun 30, 2025 -7.99 Mn
Mar 31, 2025 -9.26 Mn
Dec 31, 2024 -8.21 Mn
Sep 30, 2024 1.66 Mn
Jun 30, 2024 -8.56 Mn
Mar 31, 2024 -8.75 Mn
Dec 31, 2023 -9.22 Mn
Sep 30, 2023 -10.53 Mn
Jun 30, 2023 -9.65 Mn
Mar 31, 2023 -14.05 Mn
Dec 31, 2022 -1.70 Mn
Sep 30, 2022 -13.41 Mn
Jun 30, 2022 -14.01 Mn
Mar 31, 2022 -14.44 Mn
Dec 31, 2021 -14.95 Mn
Sep 30, 2021 -13.69 Mn